01/30/25 – Epirium Bio Announces First Participants Dosed in Phase I Clinical Trial Evaluating MF-300 for the Treatment of Sarcopenia

Epirium Bio Inc published this content on January 30, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 04, 2026 at 06:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]